Literature DB >> 17312111

Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.

Jang-Hann J Chu1, Cern-Cher S Chiang, Mah-Lee Ng.   

Abstract

The domain III of the West Nile virus (WNV) envelope glycoprotein (E) was shown to serve as virus attachment domain to the cellular receptor, and neutralizing Abs have been mapped to this specific domain. In this study, domain III of the WNV E protein (WNV E DIII) was expressed as a recombinant protein and its potential as a subunit vaccine candidate was evaluated in BALB/C mice. Immunization of WNV E DIII protein with oligodeoxynucleotides (CpG-DNA) adjuvant by i.p. injection was conducted over a period of 3 wk. The immunized mice generated high titer of WNV-neutralizing Abs. Murine Ab against WNV E DIII protein was also capable of neutralizing Japanese encephalitis virus. The IgG isotypes generated were predominantly IgG2a in the murine sera against the recombinant protein. Splenocyte cultures from the mice coadministrated with WNV E DIII protein and CpG secreted large amounts of IFN-gamma and IL-2 and showed proliferation of T cells in the presence of WNV E DIII protein. Overall, this study highlighted that recombinant WNV E DIII protein delivered in combination with CpG adjuvant to mice generated a Th1 immune response type against WNV and can serve as a potential vaccine to prevent WNV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312111     DOI: 10.4049/jimmunol.178.5.2699

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Authors:  Nicholas O Fischer; Ernesto Infante; Tomohiro Ishikawa; Craig D Blanchette; Nigel Bourne; Paul D Hoeprich; Peter W Mason
Journal:  Bioconjug Chem       Date:  2010-06-16       Impact factor: 4.774

Review 2.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

3.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

4.  A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Yan-Ru Feng; Karla A Fenton; Katharine N Bossart; Lianying Yan; Yee-Peng Chan; Christopher C Broder; Thomas W Geisbert
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

5.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

6.  PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype.

Authors:  Petr Danecek; Wenzhe Lu; Catherine H Schein
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

7.  Detection of specific antibodies against tembusu virus in ducks by use of an E protein-based enzyme-linked immunosorbent assay.

Authors:  Xiuchen Yin; Rang Lv; Xiaodan Chen; Ming Liu; Ronghong Hua; Yun Zhang
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

8.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

9.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

10.  IL-10 signaling blockade controls murine West Nile virus infection.

Authors:  Fengwei Bai; Terrence Town; Feng Qian; Penghua Wang; Masahito Kamanaka; Tarah M Connolly; David Gate; Ruth R Montgomery; Richard A Flavell; Erol Fikrig
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.